## Cristina Lucia Ronchi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9692/publications.pdf

Version: 2024-02-01

186209 143943 3,491 56 28 57 citations h-index g-index papers 59 59 59 3758 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	7.7	482
2	Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome. New England Journal of Medicine, 2014, 370, 1019-1028.	13.9	355
3	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	1.8	274
4	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncology, The, 2015, 16, 426-435.	5.1	272
5	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology, 2015, 156, 3895-3908.	1.4	153
6	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	5.5	129
7	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. European Urology, 2014, 65, 832-838.	0.9	121
8	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1686-1695.	1.8	105
9	Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. European Journal of Endocrinology, 2016, 174, 363-372.	1.9	100
10	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4511-4523.	1.8	92
11	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4323-4332.	1.8	79
12	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3526-3538.	1.8	65
13	Driver mutations in USP8 wild-type Cushing's disease. Neuro-Oncology, 2019, 21, 1273-1283.	0.6	65
14	Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocrine-Related Cancer, 2009, 16, 907-918.	1.6	63
15	Next-generation therapies for adrenocortical carcinoma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101434.	2.2	61
16	Long-Term Evaluation of Postoperative Acromegalic Patients in Remission with Previous and Newly Proposed Criteria. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1377-1382.	1.8	58
17	Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence?. PLoS ONE, 2013, 8, e73959.	1.1	58
18	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440.	3.4	57

#	Article	IF	Citations
19	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 499-508.	5.5	55
20	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3205.	1.8	44
21	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	1.1	41
22	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. European Journal of Endocrinology, 2022, 186, 25-36.	1.9	41
23	Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2251-E2260.	1.8	38
24	EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. European Journal of Endocrinology, 2014, 171, R1-R11.	1.9	37
25	cAMP signaling in cortisol-producing adrenal adenoma. European Journal of Endocrinology, 2015, 173, M99-M106.	1.9	32
26	Alterations in Protein Kinase A Substrate Specificity as a Potential Cause of Cushing Syndrome. Endocrinology, 2019, 160, 447-459.	1.4	32
27	Single Nucleotide Polymorphism Microarray Analysis in Cortisol-Secreting Adrenocortical Adenomas Identifies New Candidate Genes and Pathways. Neoplasia, 2012, 14, 206-IN13.	2.3	31
28	Adrenocortical tumors and insulin resistance: What is the first step?. International Journal of Cancer, 2016, 138, 2785-2794.	2.3	29
29	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2535-2546.	1.8	29
30	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocrine-Related Cancer, 2015, 22, 531-543.	1.6	27
31	Livin/BIRC7 expression as malignancy marker in adrenocortical tumors. Oncotarget, 2017, 8, 9323-9338.	0.8	27
32	Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancer. Endocrine-Related Cancer, 2017, 24, 319-327.	1.6	24
33	RNA Sequencing and Somatic Mutation Status of Adrenocortical Tumors: Novel Pathogenetic Insights. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4459-e4473.	1.8	24
34	Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 219.	1.5	23
35	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359.	1.7	23
36	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. Annals of Surgical Oncology, 2019, 26, 531-538.	0.7	22

#	Article	IF	CITATIONS
37	Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging. Clinical Chemistry, 2019, 65, 1276-1286.	1.5	19
38	Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma. Frontiers in Endocrinology, 2020, 11, 597878.	1.5	18
39	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2642-2653.	1.8	18
40	Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study. European Journal of Endocrinology, 2020, 183, 453-462.	1.9	18
41	Differential expression of the protein kinase A subunits in normal adrenal glands and adrenocortical adenomas. Scientific Reports, 2017, 7, 49.	1.6	17
42	Adrenal disorders: Is there Any role for vitamin D?. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 355-362.	2.6	17
43	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. Hormones and Cancer, 2016, 7, 211-218.	4.9	16
44	ERCC1 as predictive biomarker to platinum-based chemotherapy in adrenocortical carcinomas. European Journal of Endocrinology, 2018, 178, 181-188.	1.9	15
45	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 578-584.	0.6	15
46	Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment. Cancers, 2021, 13, 4200.	1.7	13
47	Identifying New Potential Biomarkers in Adrenocortical Tumors Based on mRNA Expression Data Using Machine Learning. Cancers, 2021, 13, 4671.	1.7	12
48	Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives. Endocrine, 2018, 62, 506-516.	1.1	11
49	Intratumor heterogeneity of prognostic DNA-based molecular markers in adrenocortical carcinoma. Endocrine Connections, 2020, 9, 705-714.	0.8	10
50	Genomic and sequence variants of protein kinase A regulatory subunit type $1\hat{l}^2$ (PRKAR1B) in patients with adrenocortical disease and Cushing syndrome. Genetics in Medicine, 2021, 23, 174-182.	1.1	8
51	PKA $\hat{\text{Cl}}\pm$ subunit mutation triggers caspase-dependent $\hat{\text{RIII}}^2$ subunit degradation via Ser <sup>114</sup> phosphorylation. Science Advances, 2021, 7, .	4.7	4
52	Steroid Sulfation in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3385-3397.	1.8	4
53	The role of molecular profiling in adrenocortical carcinoma. Clinical Endocrinology, 2021, , .	1.2	4
54	cAMP/protein kinase A signalling pathway and adrenocortical adenomas. Current Opinion in Endocrine and Metabolic Research, 2019, 8, 15-21.	0.6	2

#	Article	IF	CITATIONS
55	Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma. European Journal of Endocrinology, 2022, 186, 607-617.	1.9	2
56	Adrenocortical tumors: challenges and recent advances in diagnosis and treatment. Minerva Endocrinologica, 2018, 44, 1-3.	1.7	1